Products

Tickr

Finansnyheter utan brus

tickr.se Finance / Financial Data & Research

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Sep 2026
MRR
$0
0.0%30d2026-07-30
Entry price
Unknown
No monthly subscription pricing
Creators
Tickr.se
@tickrse· 773 followers
Launched
13mo ago
2025-10-14 · Est.

Traffic & revenue

Monthly visitsData through Sep 2026 · Oct 2026 pending
Verified monthly revenueRevenue data stopped at 2025-11-11
  • Nov 2025$20.95
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    AI-powered financial news for Swedish investors

    Apr 16 · 7mo agoLaunch page

  • Launched on TrustMRRLaunch

    Programvara för finansiella analyser

    Oct 14, 2025 · 13mo agoLaunch page

Traffic sources

Sep 2026

Traffic breakdown

Channels

  • Direct37%
  • Organic Search31%
  • Referrals13%
  • Social6%
  • Other13%

Countries

  • Sweden100%

Search

Domain authority 4Domain registered 2025-09-23

KeywordMonthly volume
tradedoubler31.4K
yubico15.1K
adtraction12.8K
oljepriset960
nederman730

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2026-07-30

Key pages

Weekly snapshots
Home
tickr.se/ Snapshot 2026-11-04

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does Tickr get?
Vaneform estimates <5K website visits in 2026-09. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Tickr and what platforms does it support?
Tickr is catalogued under Financial Data & Research: Finansnyheter utan brus. Supported platforms: Web.
What is Tickr's publicly disclosed revenue?
TrustMRR records verified MRR of $0 observed on 2026-07-30.Source

Related products in this category

Finance / Financial Data & Research

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.